Drug name - Korsuva

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10793596 CARA THERAP Synthetic peptide amides
Nov, 2027

(5 years from now)

US10017536 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(5 years from now)

US8536131 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(5 years from now)

US7727963 CARA THERAP Synthetic peptide amides
Nov, 2027

(5 years from now)

US7713937 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(5 years from now)

US7402564 CARA THERAP Synthetic peptide amides
Nov, 2027

(5 years from now)

CN101627049A CARA THERAP Synthetic Phthalamide
Nov, 2027

(5 years from now)

CN101627049B CARA THERAP Synthetic Phthalamide
Nov, 2027

(5 years from now)

CN101535336B CARA THERAP Synthesizing Phthalic Amide And The Dimer
Nov, 2027

(5 years from now)

CN101535336A CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

IN200903250P4 CARA THERAP Synthetic Peptide Amides
Nov, 2027

(5 years from now)

IN298634B CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

IN298624B CARA THERAP Synthetic Peptide Amides
Nov, 2027

(5 years from now)

IN200903251P4 CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

EP2064228A2 CARA THERAP Synthetic Peptide Amides
Nov, 2027

(5 years from now)

EP2064228B1 CARA THERAP Synthetic Peptide Amides
Nov, 2027

(5 years from now)

EP2079756A2 CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

EP2079756B1 CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10138270 CARA THERAP Synthetic peptide amides Nov, 2027

(5 years from now)

US9359399 CARA THERAP Synthetic peptide amides Nov, 2027

(5 years from now)

US9334305 CARA THERAP Synthetic peptide amides and dimers thereof Nov, 2027

(5 years from now)

US8486894 CARA THERAP Synthetic peptide amides and dimeric forms thereof Nov, 2027

(5 years from now)

US8236766 CARA THERAP Uses of synthetic peptide amides Nov, 2027

(5 years from now)

US8217007 CARA THERAP Synthetic peptide amides Nov, 2027

(5 years from now)

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.